By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Morphotek said today that it has entered into two agreements with Fox Chase Cancer Center to acquire clinical samples that it will use to develop companion diagnostic assays for use with drugs currently under development at Morphotek.

Morphotek, a subsidiary of Eisai, said it will fund prospective and archival sample collection programs at Fox Chase to obtain samples from patients who are newly diagnosed with cancer or are being treated for a variety of tumor types.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.